Vanda Pharmaceuticals (VNDA)

$4.97 0.00 (0.00%)

16:00 EDT VNDA Stock Quote Delayed 30 Minutes

Why Is Vanda Pharmaceuticals (VNDA) Stock Up 34% Today?

By William White, InvestorPlace Writer Apr 17, 2024

Vanda Pharmaceuticals stock is heading higher on Wednesday as investors in VNDA learn of an acquisition offer for their shares.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Why Is Vanda Pharmaceuticals (VNDA) Stock Up 33% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

More Articles

Volume:

Previous Close -

Market Cap 276.52M

PE Ratio 124.25

EPS 0.04

Volume (Avg. Vol.) 2,362

Day's Range -

52-Week Range $3.30 - $7.00

Dividend & Yield N/A (N/A)

VNDA Stock Predictions, Articles, and Vanda Pharmaceuticals News

From InvestorPlace
From the Web

7 Chip Stocks to Buy as the Supply Crunch Carries On

By Tezcan Gecgil, InvestorPlace Contributor Nov 30, 2021

In 2022, these seven leading chip stocks stand to benefit from growth in both established and emerging technologies.

7 Healthcare Stocks for a Reopening World

By Tezcan Gecgil, InvestorPlace Contributor Apr 26, 2021

The stock market is at all-time highs, and the world is starting to reopen. But these healthcare stocks have more growth opportunities ahead.

4 Top Efficient Stocks to Buy for Stellar Returns

By Apr 26, 2018

A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with its price performance. Com....

13 Biotechnology Stocks to Buy Now

By Portfolio Grader Nov 28, 2016

This week, 13 Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

7 Biotechnology Stocks to Buy Now

By Portfolio Grader Nov 21, 2016

The grades of 7 Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

5 Stocks With Superb Earnings Revisions — SNOW AKER RPT BBRY VNDA

By Portfolio Grader Oct 21, 2016

This week, these five stocks have the best ratings in Earnings Revisions, one of the eight Fundamental Categories on Portfolio Grader.

5 Stocks With Prime Earnings Revisions — SNOW VNDA AKER RPT ACH

By Portfolio Grader Oct 7, 2016

This week, these five stocks have the best ratings in Earnings Revisions, one of the eight Fundamental Categories on Portfolio Grader.

Biggest Movers in Manufacturing Stocks Now – SPU MESO KTOV CCUR

By Portfolio Grader Oct 6, 2016

The following stocks were the biggest movers and shakers in the Manufacturing sector today.

5 Stocks With Prime Earnings Revisions — SNOW VNDA GRPN AKER ACH

By Portfolio Grader Sep 30, 2016

This week, these five stocks have the best ratings in Earnings Revisions, one of the eight Fundamental Categories on Portfolio Grader.

5 Stocks With Great Earnings Revisions — SNOW VNDA AKER GRPN ACH

By Portfolio Grader Sep 23, 2016

This week, these five stocks have the best ratings in Earnings Revisions, one of the eight Fundamental Categories on Portfolio Grader.

5 Stocks With Prime Earnings Revisions — VNDA ACH RICE NSA AEM

By Portfolio Grader Sep 16, 2016

This week, these five stocks have the best ratings in Earnings Revisions, one of the eight Fundamental Categories on Portfolio Grader.

5 Stocks With Strong Earnings Revisions — VNDA PBR.A GPOR ACH NSA

By Portfolio Grader Sep 9, 2016

This week, these five stocks have the best ratings in Earnings Revisions, one of the eight Fundamental Categories on Portfolio Grader.

6 Biotechnology Stocks to Buy Now

By Portfolio Grader Sep 5, 2016

The grades of 6 Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

Hottest Manufacturing Stocks Now – VNDA PDEX DMPI YECO

By Portfolio Grader Aug 25, 2016

The following stocks were moving the Manufacturing sector today.

18 Biotechnology Stocks to Sell Now

By Portfolio Grader Jun 13, 2016

This week, 18 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Biggest Movers in Manufacturing Stocks Now – PSDV CCXI CFRX STML

By Portfolio Grader May 30, 2016

The following stocks were moving the Manufacturing sector today.

Hottest Manufacturing Stocks Now – RLYP VNDA VRX IXYS

By Portfolio Grader May 27, 2016

The following stocks were the biggest movers and shakers in the Manufacturing sector today.

3 Great ETFs for a Biotech Rebound – BBP CNCR XBI

By Todd Shriber, InvestorPlace Contributor May 2, 2016

Biotech stocks and ETFs have recently been rebounding in impressive fashion. Tactical investors might want to take a look at BBP, XBI and CNCR.

6 Biotechnology Stocks to Buy Now

By Portfolio Grader Dec 31, 2014

Six biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").

Why Avis, Chesapeake Energy, and Vanda Pharmaceuticals are 3 of Today’s Best Stocks

By Ethan Roberts, InvestorPlace Contributor Dec 23, 2014

A revision higher in the Commerce Department's Q3 GDP sends Wall Street traders home happy again, while Avis, Chesapeake Energy, and Vanda Pharmaceuticals all prosper.

Why Vanda Pharmaceuticals Stock Is Skyrocketing Today

From The Motley Fool Apr 17, 2024

Future Pak wants Vanda, but Vanda doesn't want Future Pak.

Vanda updates on FDA review for Hetlioz label expansion (NASDAQ:VNDA)

From Seeking Alpha Feb 5, 2024

Vanda Pharmaceuticals (VNDA) faces potential label expansion setbacks for sleep disorder therapy Hetlioz as the FDA cites deficiencies in its review. Read more here.

Fed court allows Vanda lawsuit against FDA to move forward (NASDAQ:VNDA)

From Seeking Alpha Jan 19, 2024

Vanda (VNDA) is moving forward with its lawsuit against the FDA after the US Court of Federal Claims denied the government's motion to dismiss. Read more here.

Vanda stock jumps on $100M license deal for MS drug from J&J unit (NASDAQ:VNDA)

From Seeking Alpha Dec 7, 2023

Vanda Pharmaceuticals acquires U.S. and Canadian rights to Ponvory, a relapsing multiple sclerosis drug, from J&J unit Actelion for $100M.

Why Shares of Vanda Pharmaceuticals Are Dropping on Tuesday

From The Motley Fool Sep 5, 2023

The pharmaceutical company's stock hit another 52-week low.

Why Vanda Pharmaceuticals Stock Crawled Higher Today

From The Motley Fool Feb 9, 2023

A solid earnings beat drove the company's share price upward.

ADVERTISEMENT